PolyActiva Strengthens Executive Team to Accelerate U.S. Expansion and Advance Late-Stage Clinical Development of Sustained-Release Ocular Therapies PolyActiva, a clinical-stage biopharmaceutical company at the forefront of innovation in ocular drug…
Tempus Secures FDA 510(k) Clearance for AI-Driven ECG-Low EF Software, Expanding Capabilities in Cardiovascular Risk Detection Tempus AI, Inc. (NASDAQ: TEM), a trailblazer in applying artificial intelligence to drive precision…
Genascence Secures RMAT Designation for Groundbreaking Gene Therapy GNSC-001 in Knee Osteoarthritis, Signaling a Major Step Forward in Regenerative Medicine Genascence Corporation, a clinical-stage biotechnology company pioneering gene therapy solutions…
Satellos Bioscience Names Renowned Neuromuscular Expert Dr. Wildon Farwell as Chief Medical Officer to Advance Duchenne Therapy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotechnology company pioneering small molecule…
Veranex Launches Industry’s First Innovation CRO to Accelerate MedTech R&D in a Tight Capital Climate Veranex, a global leader in integrated product development and contract research services for medical technology,…
KalVista Pharmaceuticals Secures UK MHRA Approval for EKTERLY® (sebetralstat), Paving the Way for First Oral On-Demand Treatment for Hereditary Angioedema in the Region KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage…
C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative…
Enveric Biosciences’ Lead Candidate EB-003 Shows Promising Preclinical Efficacy in PTSD Model, Signaling a Potential Breakthrough in Neuroplasticity-Based Psychiatric Treatment Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company advancing a…
EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered…
Vistagen Earns Dual Honors for Mental Health Advocacy and Exceptional Workplace Culture in 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company revolutionizing neuroscience with its novel nose-to-brain neurocircuitry platform,…
ZYUS Life Sciences Appoints Dr. Julie Stakiw as Chief Medical Officer to Advance Phase 2 Oncology Pain Program and Strengthen Clinical Development Leadership In a pivotal step toward accelerating its…
JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical…